These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 32436445)

  • 21. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.
    Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M
    J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
    Subramanian K; Nalli A; Senthil V; Jain S; Nayak A; Bhat A
    Adv Ther; 2020 Oct; 37(10):4107-4131. PubMed ID: 32809210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
    Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
    J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
    Abena PM; Decloedt EH; Bottieau E; Suleman F; Adejumo P; Sam-Agudu NA; Muyembe TamFum JJ; Seydi M; Eholie SP; Mills EJ; Kallay O; Zumla A; Nachega JB
    Am J Trop Med Hyg; 2020 Jun; 102(6):1184-1188. PubMed ID: 32323646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
    Li H; Wang YM; Xu JY; Cao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
    Khan Z; Karataş Y; Rahman H
    Adv Ther; 2020 Jun; 37(6):2575-2579. PubMed ID: 32350686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.
    Bhattacharyya A; Kumar S; Sarma P; Kaur H; Prajapat M; Shekhar N; Bansal S; Avti P; Hazarika M; Sharma S; Mahendru D; Prakash A; Medhi B
    Indian J Pharmacol; 2020; 52(4):313-323. PubMed ID: 33078733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on novel COVID-19 pandemic: a battle between humans and virus.
    Prajapati S; Sharma M; Kumar A; Gupta P; Narasimha Kumar GV
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5819-5829. PubMed ID: 32495921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Meo SA; Klonoff DC; Akram J
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
    J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.